Pharmacokinetics of verapamil in patients with renal failure

Eur J Clin Pharmacol. 1985;28(4):405-10. doi: 10.1007/BF00544358.


The pharmacokinetics of verapamil was studied in patients with end-stage chronic renal failure and in normal subjects after i.v. injection of 3 mg and a single oral dose of 80 mg. Plasma levels of verapamil and its active metabolite norverapamil were measured by HPLC. After i.v. injection, the terminal phase half-life and total plasma clearance of verapamil in both groups were similar. Haemodialysis did not change the time course of plasma verapamil levels after i.v. administration. After a single oral dose, the plasma levels of verapamil and norverapamil in both groups of subjects were similar. Subsequently, normal volunteers and patients with renal failure were treated for 5 days with oral verapamil 80 mg t.d.s. There was no difference between the 2 groups of subjects in the trough and peak levels of verapamil or of norverapamil. Intravenous and oral administration of the calcium channel blocking agent had similar effects on blood pressure, heart rate and the PR-interval in the electrocardiogram in both groups. The study demonstrated that the disposition of verapamil was similar in normal subjects and in patients with renal failure.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Female
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / metabolism*
  • Kinetics
  • Male
  • Middle Aged
  • Renal Dialysis
  • Verapamil / analogs & derivatives
  • Verapamil / blood
  • Verapamil / metabolism*


  • norverapamil
  • Verapamil